Rigel Pharmaceuticals Dossier
Qualitative Analysis
Business overview
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a commercial-stage biotechnology company dedicated to discovering, developing, and providing novel small-molecule therapies for patients with hematologic disorders and cancer. The company's commercial portfolio features three key products: TAVALISSE (fostamatinib disodium hexahydrate) for chronic immune thrombocytopenia (ITP); REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation; and GAVRETO (pralsetinib) for metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer. Rigel has established strategic partnerships with major pharmaceutical players, including licensing agreements with Kissei Pharmaceutical, Grifols, and Eli Lilly. In June 2026, Rigel closed a major global licensing agreement to develop, manufacture, and commercialize VEPPANU (vepdegestrant), an oral PROTAC therapy targeting ER+/HER2- advanced or metastatic breast cancer.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding Rigel's commercial footprint in hematology and oncology by launching newly licensed or acquired assets, specifically focusing on the commercialization of VEPPANU (vepdegestrant) starting in August 2026.
Expected impact: Diversifies revenue streams beyond the flagship product TAVALISSE and accelerates long-term commercial growth.
Advancing the clinical development of R289, a dual IRAK1 and IRAK4 inhibitor, for patients with lower-risk myelodysplastic syndromes (MDS) who are transfusion-dependent.
Expected impact: Establishes a high-value, wholly-owned pipeline asset addressing a significant unmet medical need in hematology.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC (PROteolysis TArgeting Chimera) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
Terms: $70.0 million upfront payment (split evenly between Arvinas and Pfizer), $15.0 million upon completion of transition activities, up to $320.0 million in potential regulatory and commercial milestones, and tiered royalties ranging from mid-teens to mid-twenties on net sales.